Cullinan Therapeutics
Stephen Wax is an accomplished clinical development professional with extensive experience in the biopharmaceutical industry. Currently serving as Vice President of Clinical Development at Cullinan Therapeutics since May 2024, Stephen previously held similar positions at Zenas BioPharma and Neurogastrx, Inc. Stephen's career includes significant roles at EMD Serono, Inc. as Senior Medical Director and Medical Director, as well as at Hoffmann-La Roche as CSS. Earlier in their career, Stephen worked as a Rheumatologist at Brigham and Women's Hospital. Stephen holds an MD and PhD in Rheumatology from the Icahn School of Medicine at Mount Sinai and has a foundational education from Cornell University.
This person is not in the org chart
Cullinan Therapeutics
1 followers
Cullinan Therapeutics is dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.